Keywords: تراستوزومب، هرسپتین; breast cancer; cardiotoxicity; trastuzumab;
مقالات ISI تراستوزومب، هرسپتین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: تراستوزومب، هرسپتین; LV; left ventricle; GLS; global longitudinal strain; CMR; cardiac magnetic resonance; LVEF; left ventricular ejection fraction; ECOG; Eastern Cooperative Oncology Group; HER2; human epidermal growth factor receptor 2; NYHA; New York Heart Association; Nt-
Keywords: تراستوزومب، هرسپتین; Esophagus; Squamous cell carcinoma; Adenocarcinoma; Gastric carcinoma; Molecular genetics; HER-2; Trastuzumab; Next-generation sequencing;
Keywords: تراستوزومب، هرسپتین; breast cancer; cardiac monitoring; cardio-oncology; cardiotoxicity; trastuzumab; HF; heart failure; MUGA; multiple-gated acquisition;
Keywords: تراستوزومب، هرسپتین; Cancer therapy-mediated cardiotoxicity; Chemotherapy-induced cardiomyopathy; Anthracyclines; HER2-targeted therapies; Trastuzumab; Radiotherapy-induced cardiotoxicity; β-Blockers; Renin-angiotensin inhibitors;
Keywords: تراستوزومب، هرسپتین; Multifunctional gold nanoparticles; Anti-biofouling; ERBB2-positive breast cancer cells; Trastuzumab; FACS; ICP-OES; DF-HIS;
Keywords: تراستوزومب، هرسپتین; Lymphatic; Biologic; Therapeutic proteins; Pharmacokinetics; Biodistribution; Intravenous; Trastuzumab; Interferon; Pegylated interferon; IFN-PEG40; 60 kDa Pegylated interferon α2a, PEGASYS®; IFN-PEG12;  ~ 31 kDa Pegylated interferon α2b, PEG-Intro
Keywords: تراستوزومب، هرسپتین; Monoclonal antibody; Antibody drug conjugate; Stability profile; SE-HPLC; Trastuzumab; Trastuzumab emtansine;
Keywords: تراستوزومب، هرسپتین; Cardio-oncology; Chemotherapy; Thrombectomy; Thrombus; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Monoclonal antibody therapy; ADCC; Trastuzumab; HER2; Tyrosine kinase inhibitors; LDH assay;
Keywords: تراستوزومب، هرسپتین; Aldosterone; Cardiovascular toxicity; Radiotherapy; Spironolactone; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Breast cancer; Primary metastatic disease; Breast surgery; Trastuzumab; Bevacizumab;
Keywords: تراستوزومب، هرسپتین; Adjuvant; Breast cancer; HER2/neu; Herceptin; Subcutaneous; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; arginine metabolism; cardio-oncology; cardiotoxicity; doxorubicin; nitrosative stress; trastuzumab; ADMA; asymmetric dimethylarginine; BMI; body mass index; CI; confidence interval; CTRCD; cancer therapeutics-related cardiac dysfunction; IQR; interquart
Keywords: تراستوزومب، هرسپتین; Esophagogastric cancer; HER2; Targeted therapy; Trastuzumab; Pertuzumab; TDM-1; Lapatinib;
Keywords: تراستوزومب، هرسپتین; HER2-Positive breast cancer; Biosimilars; Anti-HER2 therapy; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Heart failure; Cancer; Cardiotoxicity; Cardioprotection; Anthracyclines; Trastuzumab; Cardio-oncology; Myocardial dysfunction;
Keywords: تراستوزومب، هرسپتین; PT, phyllodes tumor; BC, breast cancer; FA, fibroadenomaBreast cancer; Phyllodes tumor; Docetaxel; Trastuzumab; Pertuzumab
Keywords: تراستوزومب، هرسپتین; Adjuvant therapy; biological markers; breast cancer; oncoplastic; sentinel node biopsy; trastuzumab
Keywords: تراستوزومب، هرسپتین; Cardiotoxicity; chemotherapy; trastuzumab; tyrosine kinase inhibitor
Keywords: تراستوزومب، هرسپتین; Cardiomyopathy; Trastuzumab; Lapatinib; Pertuzumab; Breast cancer
Keywords: تراستوزومب، هرسپتین; cancer du sein; cytotoxique; lapatinib; radiothérapie; tamoxifène; thérapie ciblée; trastuzumabbreast cancer; cytotoxic; lapatinib; radiotherapy; tamoxifen; targeted therapy; trastuzumab
Keywords: تراستوزومب، هرسپتین; Breast cancer; Cardiac outcomes; Chemotherapy; HER2 positive; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Metastatic breast cancer; Metastatic colorectal cancer; Trastuzumab; Bevacizumab; Anthracycline; Cyclophosphamide; Paclitaxel; Irinotecan; Fluorouracil; Leucovorin;
Keywords: تراستوزومب، هرسپتین; Echocardiography; Strain; Cardiotoxicity; Trastuzumab; Early breast cancer;
Keywords: تراستوزومب، هرسپتین; Hydrophilic interaction chromatography; HILIC; Insulins; Interferon α-2b; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Metastatic breast cancer; HER2; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Resistance; Management; Novel therapy;
Keywords: تراستوزومب، هرسپتین; Cancer therapy; Targeted therapy; Resistance mechanisms; Intrinsic resistance; Acquired resistance; Trastuzumab
Keywords: تراستوزومب، هرسپتین; brain metastasis; breast cancer; HER2; trastuzumab; whole-brain irradiation
Keywords: تراستوزومب، هرسپتین; Childhood cancer; Adriamycin; Breast cancer; Trastuzumab; Autonomic dysfunction; Hypothermia;
Keywords: تراستوزومب، هرسپتین; Economic evaluation; Health technology assessment; Trastuzumab; Metastatic breast cancer; Biosimilars;
Keywords: تراستوزومب، هرسپتین; Trastuzumab; Fluid retention; Cardiotoxicity; Haemodynamics; Echocardiography; Healthy volunteers
Keywords: تراستوزومب، هرسپتین; Early breast cancer; Elderly patients; Her2 overexpression; Trastuzumab; Non-interventional study;
Keywords: تراستوزومب، هرسپتین; Hydrogel; Hyaluronic acid; Hyaluronidase; Sustained release; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Near infrared photoimmunotherapy; Bioluminescence; HER2 receptor; Lung metastases; PIT; photoimmunotherapy; EGFR; epidermal growth factor receptor; tra; trastuzumab; IR700; IRDye700DX; NIR; near-infrared;
Keywords: تراستوزومب، هرسپتین; Trastuzumab; HER2; Biomarker discovery; Drug resistance; Breast cancer;
Keywords: تراستوزومب، هرسپتین; Speckle tracking echocardiography; Cardiotoxicity; Chemotherapy; Trastuzumab; Anthracyclines;
Keywords: تراستوزومب، هرسپتین; cardiotoxicity; anthracyclines; trastuzumab; oxidative stress
Keywords: تراستوزومب، هرسپتین; Breast carcinoma; Trastuzumab; Thrombocytopenia;
Keywords: تراستوزومب، هرسپتین; Breast cancer; Trastuzumab; Metastatic treatment;
Keywords: تراستوزومب، هرسپتین; Trastuzumab; heart failure; congestive; cardiomyopathy
Keywords: تراستوزومب، هرسپتین; Trastuzumab; Small tumours; Elderly; Early breast cancer; Adjuvant therapy; HER2-positive;
Keywords: تراستوزومب، هرسپتین; HER2 positive breast cancer; Trastuzumab; HER2 testing; HER2 concordance; Immunohistochemistry; In situ hybridisation
Keywords: تراستوزومب، هرسپتین; Adherence; Aromatase inhibitors; Tamoxifen; Toxicity; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Breast cancer; Trastuzumab; Drug reimbursement; Health policy; Health expenditure; European Union;
Keywords: تراستوزومب، هرسپتین; Cardiotoxicity; Mouse model; Echocardiography; Hemodynamics; cTnI; Cardiac troponin I; Dox; Doxorubicin; ErbB2; Epidermal growth factor receptor type 2; HF; Heart failure; LV; Left ventricular; LVEDV; Left ventricular end-diastolic volume; LVEF; Left vent
Keywords: تراستوزومب، هرسپتین; Chemotherapy; Doxorubicin; Trastuzumab; Left ventricular dysfunction; Three-dimensional echocardiography; Early detection; Strain; Biomarkers; ASE; American Society of Echocardiography; BNP; Brain-type natriuretic peptide; CAD; Coronary artery disease; CM
Keywords: تراستوزومب، هرسپتین; Strain; Strain rate; Cardiotoxicity; Trastuzumab; Breast cancer; AUC; Area under the curve; CI; Confidence interval; EF; Ejection fraction; GLS; Global longitudinal peak systolic strain; GLSR-E; Global longitudinal early diastolic strain rate; GLSR-S; Glo
Keywords: تراستوزومب، هرسپتین; Affinity screening; Anti-idiotype; Biolayer interferometry; Cetuximab; HuCAL; Trastuzumab;
Keywords: تراستوزومب، هرسپتین; Breast cancer; Adverse events; Trastuzumab; Pertuzumab; Lapatinib; Bevacizumab; Trastuzumab-emtansine; Everolimus; ABC; advanced breast cancer; QoL; quality of life; AE; adverse event; HER2; human epidermal growth factor receptor type 2; LVEF; left ventri